Raajit Rampal: Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis
Raajit Rampal, an Associate Member at the Memorial Sloan Kettering Cancer Center, recently shared on X about recent paper he and colleagues co-authored, titled “Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial” published on Nature Medicine.
Authors: Raajit K. Rampal, Sebastian Grosicki, Dominik Chraniuk, Elisabetta Abruzzese, Prithviraj Bose, Aaron T. Gerds, Alessandro M. Vannucchi, Francesca Palandri, Sung-Eun Lee, Vikas Gupta, Alessandro Lucchesi, Stephen T. Oh, Andrew T. Kuykendall, Andrea Patriarca, Alberto Álvarez-Larrán, Ruben Mesa, Jean-Jacques Kiladjian, Moshe Talpaz, Joseph M. Scandura, David Lavie, Morgan Harris, Sarah-Katharina Kays, Qing Li, Rainer Boxhammer, John Mascarenhas
“Out today in Nature Medicine phase 3 data from the MANIFEST-2 study.
The key preclinical observations that led to investigation of BET inhibition in MF came from showing that NF-kB output and disease features in MF murine models were attenuated by BETi.
A phase II study demonstrated that the BET inhibitor pelabresib in combination with RUX was tolerable and demonstrated efficacy beyond what was observed historically with RUX alone.
MANIFEST-2 demonstrate that the combination of RUX+PELA was superior to RUX alone in spleen volume reduction (primary endpoint). Symptom burden reduction was similar between both arms.
Importantly, reduction of key cytokines (IL-8) and bone marrow fibrosis was better with combination than RUX alone.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023